Compare DSWL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | TCRX |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 63.6M |
| IPO Year | 2000 | 2021 |
| Metric | DSWL | TCRX |
|---|---|---|
| Price | $3.30 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 9.1K | ★ 465.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $69.75 |
| P/E Ratio | $4.59 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $2.03 | $0.88 |
| 52 Week High | $4.48 | $2.57 |
| Indicator | DSWL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 61.50 |
| Support Level | $3.27 | $1.16 |
| Resistance Level | $3.38 | $1.23 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 2.22 | 71.80 |
Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.